138 related articles for article (PubMed ID: 29912759)
1. Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C.
Pan CQ; Tiongson BC; Hu KQ; Han SB; Tong M; Chu D; Park J; Lee TP; Bhamidimarri KR; Ma X; Xiao PY; Mohanty SR; Wang D
J Clin Gastroenterol; 2019 Feb; 53(2):147-154. PubMed ID: 29912759
[TBL] [Abstract][Full Text] [Related]
2. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
Sirinawasatien A; Techasirioangkun T
PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
[TBL] [Abstract][Full Text] [Related]
6. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
Yin S; Barker L; White JZ; Jiles RB
J Manag Care Spec Pharm; 2019 Feb; 25(2):195-210. PubMed ID: 30698086
[TBL] [Abstract][Full Text] [Related]
9. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
Latt NL; Yanny BT; Gharibian D; Gevorkyan R; Sahota AK
World J Gastroenterol; 2017 Jul; 23(26):4759-4766. PubMed ID: 28765697
[TBL] [Abstract][Full Text] [Related]
10. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
[TBL] [Abstract][Full Text] [Related]
11. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Mizokami M; Yokosuka O; Takehara T; Sakamoto N; Korenaga M; Mochizuki H; Nakane K; Enomoto H; Ikeda F; Yanase M; Toyoda H; Genda T; Umemura T; Yatsuhashi H; Ide T; Toda N; Nirei K; Ueno Y; Nishigaki Y; Betular J; Gao B; Ishizaki A; Omote M; Mo H; Garrison K; Pang PS; Knox SJ; Symonds WT; McHutchison JG; Izumi N; Omata M
Lancet Infect Dis; 2015 Jun; 15(6):645-53. PubMed ID: 25863559
[TBL] [Abstract][Full Text] [Related]
12. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H
J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
PLoS One; 2018; 13(12):e0209299. PubMed ID: 30576344
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
Modi AA; Nazario HE; Gonzales GR; Gonzalez SA
Aliment Pharmacol Ther; 2018 May; 47(10):1409-1415. PubMed ID: 29569736
[TBL] [Abstract][Full Text] [Related]
15. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients.
Babatin MA; AlGhamdi AS; Assiri AM; AlBiladi H; AlOthmani HS; Mogharbel MH; Mahallawi W; Asselah T; Sanai FM
Saudi J Gastroenterol; 2019; 25(1):55-60. PubMed ID: 30117490
[TBL] [Abstract][Full Text] [Related]
16. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
Shin HP; Burman B; Kozarek RA; Zeigler A; Wang C; Lee H; Zehr T; Edwards AM; Siddique A
Gut Liver; 2017 Sep; 11(5):711-720. PubMed ID: 28651301
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
Hu C; Yuan G; Liu J; Huang H; Ren Y; Li Y; Chen X; Li W; Wu T; Deng H; Peng Y; Zhang YY; Zhou Y
Can J Gastroenterol Hepatol; 2018; 2018():3908767. PubMed ID: 30538973
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
Mangia A; Susser S; Piazzolla V; Agostinacchio E; De Stefano G; Palmieri V; Spinzi G; Carraturo I; Potenza D; Losappio R; Arleo A; Miscio M; Santoro R; Sarrazin C; Copetti M
J Hepatol; 2017 Apr; 66(4):711-717. PubMed ID: 27965158
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
20. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
